Use of SGLT2 inhibitors was associated with lower 5-year risk for chronic kidney disease and AKI compared with GLP-1 receptor ...

A new study examines how a diabetes drug may protect the kidneys from aging.

SGLT2 inhibitors were linked to better kidney outcomes than GLP-1 receptor agonists in Type 2 diabetes. Learn more about the clinical impact.

SGLT2 inhibitors are already used to treat diabetes and chronic kidney disease. This study helps explain why patients taking ...

A new study published in the Journal of American Medical Association showed that when renal protection is a primary therapeutic objective, starting treatment with an SGLT2 inhibitor (SGLT2i) ...

Please provide your email address to receive an email when new articles are posted on . Patients who received pharmacy consultation were more likely to be prescribed an SGLT2 inhibitor. More patients ...

The SGLT2 inhibitors market is experiencing robust growth, driven by the rising prevalence of type 2 diabetes and chronic kidney disease worldwide. Additionally, the expected launch of emerging SGLT2 ...

Researchers evaluate the lifetime cost-effectiveness of using SGLT2 inhibitors or GLP1 receptor agonists as first-line treatments for type 2 diabetes. Use of sodium-glucose cotransporter-2 (SGLT2) ...

Patients with SGLT2 inhibitor-associated diabetic ketoacidosis (DKA) received significantly lower doses of insulin in the first 24 hours of treatment compared with patients with type 1 diabetes DKA, ...

Sodium glucose cotransporter-2 (SGLT2) inhibitors have been described as revolutionary advances in the management of patients with type 2 diabetes, particularly in people with comorbid cardiovascular ...

Compared with placebo, SGLT2 inhibitors reduced heart failure hospitalizations among patients with history of myocardial infarction. Sodium-glucose co-transporter 2 (SGLT2) inhibitors may ...